

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/250098/publications.pdf Version: 2024-02-01



LIN LI

#	Article	IF	CITATIONS
1	Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. Journal of Clinical Oncology, 2016, 34, 1448-1454.	1.6	756
2	Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2015, 16, 619-629.	10.7	574
3	Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial. Journal of Clinical Oncology, 2013, 31, 3219-3225.	1.6	454
4	The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Communications, 2019, 39, 1-31.	9.2	418
5	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Communications, 2021, 41, 747-795.	9.2	323
6	MicroRNAs activate gene transcription epigenetically as an enhancer trigger. RNA Biology, 2017, 14, 1326-1334.	3.1	262
7	Cognitive frailty, a novel target for the prevention of elderly dependency. Ageing Research Reviews, 2015, 20, 1-10.	10.9	231
8	Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer, 2010, 10, 529.	2.6	220
9	Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer. JAMA - Journal of the American Medical Association, 2018, 319, 2486.	7.4	202
10	Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. Journal of Clinical Oncology, 2018, 36, 3031-3039.	1.6	159
11	Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discovery Today, 2018, 23, 1175-1182.	6.4	142
12	The current status of treatment for colorectal cancer in China. Medicine (United States), 2017, 96, e8242.	1.0	111
13	MicroRNA-421 regulated by HIF-1α promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer. Oncotarget, 2016, 7, 24466-24482.	1.8	103
14	Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer. Oncotarget, 2016, 7, 9815-9831.	1.8	90
15	Polarization of Monocytic Myeloid-Derived Suppressor Cells by Hepatitis B Surface Antigen Is Mediated via ERK/IL-6/STAT3 Signaling Feedback and Restrains the Activation of T Cells in Chronic Hepatitis B Virus Infection. Journal of Immunology, 2015, 195, 4873-4883.	0.8	82
16	BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer. Molecular Cancer, 2010, 9, 40.	19.2	77
17	Radical abdominal trachelectomy for cervical malignancies: Surgical, oncological and fertility outcomes in 62 patients. Gynecologic Oncology, 2011, 121, 565-570.	1.4	77
18	miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR. Oncotarget, 2015, 6, 24448-24462.	1.8	76

#	Article	IF	CITATIONS
19	Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. Journal of Hematology and Oncology, 2017, 10, 153.	17.0	70

21	Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. Molecular Oncology, 2016, 10, 1551-1558.	4.6	66
22	Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT) Journal of Clinical Oncology, 2021, 39, 160-160.	1.6	64
23	Abdominal radical trachelectomy: Is it safe for IB1 cervical cancer with tumors ≥2cm?. Gynecologic Oncology, 2013, 131, 87-92.	1.4	61
24	Associations of HLA-DP Variants with Hepatitis B Virus Infection in Southern and Northern Han Chinese Populations: A Multicenter Case-Control Study. PLoS ONE, 2011, 6, e24221.	2.5	60
25	Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 Polymorphisms Are Associated with Decreased Risk of Esophageal Squamous Cell Carcinoma in Chinese Populations. PLoS ONE, 2014, 9, e100055.	2.5	59
26	Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer. Clinical Cancer Research, 2014, 20, 4559-4573.	7.0	59
27	MicroRNA-940 promotes tumor cell invasion and metastasis by downregulating ZNF24 in gastric cancer. Oncotarget, 2015, 6, 25418-25428.	1.8	56
28	Incidence, risk factors and treatment of cervical stenosis after radical trachelectomy: A systematic review. European Journal of Cancer, 2015, 51, 1751-1759.	2.8	56
29	Final results and outcomes by prior bevacizumab exposure, skin toxicity,Âand hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. European Journal of Cancer, 2016, 68, 51-59.	2.8	56
30	Label-free Proteomic Analysis of Exosomes Derived from Inducible Hepatitis B Virus-Replicating HepAD38 Cell Line. Molecular and Cellular Proteomics, 2017, 16, S144-S160.	3.8	56
31	Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. Journal of Hematology and Oncology, 2017, 10, 22.	17.0	50
32	Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical researchâ€practice gaps, challenges, and insights. Medicinal Research Reviews, 2018, 38, 325-376.	10.5	50
33	Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer. Oncotarget, 2016, 7, 10332-10344.	1.8	50
34	The safety of apatinib for the treatment of gastric cancer. Expert Opinion on Drug Safety, 2018, 17, 1145-1150.	2.4	49
35	Prognostic Value of FGFR Gene Amplification in Patients with Different Types of Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e105524.	2.5	47
36	Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in <i>FGFR2</i> amplified gastric cancer. Oncotarget, 2015, 6, 2009-2022.	1.8	46

#	Article	IF	CITATIONS
37	A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2016, 78, 259-269.	2.3	45
38	Primary non-Hodgkin's lymphoma of the breast: eight-year follow-up experience. International Journal of Hematology, 2008, 87, 491-497.	1.6	42
39	The Combination of RAD001 and MK-2206 Exerts Synergistic Cytotoxic Effects against PTEN Mutant Gastric Cancer Cells: Involvement of MAPK-Dependent Autophagic, but Not Apoptotic Cell Death Pathway. PLoS ONE, 2014, 9, e85116.	2.5	39
40	Neurotensin is an anti-thermogenic peptide produced by lymphatic endothelial cells. Cell Metabolism, 2021, 33, 1449-1465.e6.	16.2	38
41	The Predictive and Prognostic Value of Early Metabolic Response Assessed by Positron Emission Tomography in Advanced Gastric Cancer Treated with Chemotherapy. Clinical Cancer Research, 2016, 22, 1603-1610.	7.0	37
42	Prevalence of psychological disorders in the COVID-19 epidemic in China: A real world cross-sectional study. Journal of Affective Disorders, 2021, 281, 312-320.	4.1	37
43	On what scale does it benefit the patients if uterine arteries were preserved during ART?. Gynecologic Oncology, 2014, 134, 154-159.	1.4	36
44	Discoidin domain receptors orchestrate cancer progression: A focus on cancer therapies. Cancer Science, 2021, 112, 962-969.	3.9	35
45	Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703). Oncologist, 2021, 26, e1693-e1703.	3.7	35
46	miR-449b rs10061133 and miR-4293 rs12220909 polymorphisms are associated with decreased esophageal squamous cell carcinoma in a Chinese population. Tumor Biology, 2015, 36, 8789-8795.	1.8	34
47	Histone-Related Genes Are Hypermethylated in Lung Cancer and Hypermethylated <i>HIST1H4F</i> Could Serve as a Pan-Cancer Biomarker. Cancer Research, 2019, 79, 6101-6112.	0.9	34
48	Effects of <i>IGF2BP2, KCNQ1</i> and <i>GCKR</i> polymorphisms on clinical outcome in metastatic gastric cancer treated with EOF regimen. Pharmacogenomics, 2015, 16, 959-970.	1.3	32
49	Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application. Gastroenterology Research and Practice, 2016, 2016, 1-9.	1.5	31
50	Protocadherinâ€8 promotes invasion and metastasis via laminin subunit γ2 in gastric cancer. Cancer Science, 2018, 109, 732-740.	3.9	30
51	Predictive factors of para-aortic lymph nodes metastasis in cervical cancer patients: a retrospective analysis based on 723 para-aortic lymphadenectomy cases. Oncotarget, 2017, 8, 51840-51847.	1.8	30
52	Differential microRNA expression profiling in primary tumors and matched liver metastasis of patients with colorectal cancer. Oncotarget, 2017, 8, 35783-35791.	1.8	29
53	Current Strategy for the Treatment of Ovarian Germ Cell Tumors: Role of Extensive Surgery. Current Treatment Options in Oncology, 2016, 17, 44.	3.0	28
54	Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. Chinese Journal of Cancer, 2017, 36, 97.	4.9	28

#	Article	IF	CITATIONS
55	FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC) Journal of Clinical Oncology, 2021, 39, 4010-4010.	1.6	27
56	Guide Positioning Sequencing identifies aberrant DNA methylation patterns that alter cell identity and tumor-immune surveillance networks. Genome Research, 2019, 29, 270-280.	5.5	25
57	The Survival Rate and Surgical Morbidity of Abdominal Radical Trachelectomy Versus Abdominal Radical Hysterectomy for Stage IB1 Cervical Cancer. Annals of Surgical Oncology, 2016, 23, 2953-2958.	1.5	24
58	Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men. BioMed Research International, 2015, 2015, 1-10.	1.9	23
59	Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: A study in Chinese patients. Gynecologic Oncology, 2007, 105, 769-775.	1.4	22
60	Oxidative Stress-Related Genetic Polymorphisms Are Associated with the Prognosis of Metastatic Gastric Cancer Patients Treated with Epirubicin, Oxaliplatin and 5-Fluorouracil Combination Chemotherapy. PLoS ONE, 2014, 9, e116027.	2.5	22
61	Reproductive and obstetric outcomes after abdominal radical trachelectomy (ART) for patients with early-stage cervical cancers in Fudan, China. Gynecologic Oncology, 2020, 157, 418-422.	1.4	22
62	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). European Journal of Surgical Oncology, 2020, 46, 955-966.	1.0	22
63	Mesothelial cells are not a source of adipocytes in mice. Cell Reports, 2021, 36, 109388.	6.4	22
64	UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop. Journal of Pathology, 2015, 235, 656-667.	4.5	21
65	Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. Future Oncology, 2018, 14, 2031-2044.	2.4	20
66	Open vs minimally invasive radical trachelectomy in early-stage cervical cancer: International Radical Trachelectomy Assessment Study. American Journal of Obstetrics and Gynecology, 2022, 226, 97.e1-97.e16.	1.3	20
67	Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2â€positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. Cancer Communications, 2019, 39, 1-10.	9.2	19
68	Genetic variant of PRKAA1 and gastric cancer risk in an eastern Chinese population. Oncotarget, 2015, 6, 42661-42666.	1.8	18
69	Methyl-CpG-binding domain protein 3-like 2 (MBD3L2) promotes Tet2 enzymatic activity for mediating 5mC oxidation. Journal of Cell Science, 2016, 129, 1059-71.	2.0	18
70	Expert opinions on immunotherapy for patients with colorectal cancer. Cancer Communications, 2020, 40, 467-472.	9.2	18
71	Modeling hepatoblastoma development with human fetal liver organoids reveals YAP1 activation is sufficient for tumorigenesis. Protein and Cell, 2022, 13, 683-688.	11.0	18
72	Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial Journal of Clinical Oncology, 2022, 40, LBA4011-LBA4011.	1.6	18

#	Article	IF	CITATIONS
73	DKK4 enhances resistance to chemotherapeutics 5-Fu and YN968D1 in colorectal cancer cells. Oncology Letters, 2017, 13, 587-592.	1.8	17
74	Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen. Oncotarget, 2015, 6, 39018-39027.	1.8	17
75	Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer. Oncotarget, 2015, 6, 40519-40534.	1.8	16
76	Associations of potentially functional variants in <i>IL-6</i> , <i>JAKs</i> and <i>STAT3</i> with gastric cancer risk in an eastern Chinese population. Oncotarget, 2016, 7, 28112-28123.	1.8	16
77	Establishment of Cre-mediated HBV recombinant cccDNA (rcccDNA) cell line for cccDNA biology and antiviral screening assays. Antiviral Research, 2018, 152, 45-52.	4.1	16
78	Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus. Clinical Colorectal Cancer, 2014, 13, 145-155.	2.3	15
79	<i>PSCA</i> polymorphisms and gastric cancer susceptibility in an eastern Chinese population. Oncotarget, 2016, 7, 9420-9428.	1.8	15
80	Genetic variant of <i>miR-146a</i> rs2910164 C>G and gastric cancer susceptibility. Oncotarget, 2016, 7, 34316-34321.	1.8	15
81	Expert consensus on maintenance treatment for metastatic colorectal cancer in China. Chinese Journal of Cancer, 2016, 35, 13.	4.9	14
82	An alternatively transcribed <i> <scp>TAZ</scp> </i> variant negatively regulates <scp>JAK</scp> ― <scp>STAT</scp> signaling. EMBO Reports, 2019, 20, .	4.5	14
83	Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. Cancer Biology and Therapy, 2020, 21, 891-898.	3.4	14
84	MUC1 gene polymorphism rs4072037 and susceptibility to gastric cancer: a meta-analysis. SpringerPlus, 2014, 3, 599.	1.2	13
85	Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study. BioDrugs, 2021, 35, 445-458.	4.6	13
86	Plasma microRNAâ€based signatures to predict 3â€year postoperative recurrence risk for stage II and III gastric cancer. International Journal of Cancer, 2017, 141, 2093-2102.	5.1	12
87	Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer Journal of Clinical Oncology, 2021, 39, 2514-2514.	1.6	12
88	An inhibitor-mediated beta-cell dedifferentiation model reveals distinct roles for FoxO1 in glucagon repression and insulin maturation. Molecular Metabolism, 2021, 54, 101329.	6.5	12
89	Antitumor activity and inhibitory effects on cancer stem cell-like properties of Adeno-associated virus (AAV) -mediated Bmi-1 interference driven by Bmi-1 promoter for gastric cancer. Oncotarget, 2016, 7, 22733-22745.	1.8	12
90	Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial. Cancer Immunology, Immunotherapy, 2022, 71, 1897-1908.	4.2	12

#	Article	IF	CITATIONS
91	Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study Journal of Clinical Oncology, 2021, 39, 2566-2566.	1.6	11
92	Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study. Oncotarget, 2017, 8, 37826-37834.	1.8	11
93	Menstrual pattern after abdominal radical trachelectomy. Oncotarget, 2017, 8, 53146-53153.	1.8	11
94	Prognostic significance and functional implication of immune activating receptor NKG2D in gastric cancer. Biochemical and Biophysical Research Communications, 2017, 487, 619-624.	2.1	10
95	Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials. , 2021, 9, e002114.		10
96	First-in-human phase I study of anti-HER2 ADC MRG002 in patients with relapsed/refractory solid tumors Journal of Clinical Oncology, 2020, 38, TPS1101-TPS1101.	1.6	10
97	Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 403-407.	2.2	10
98	Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy. Tumor Biology, 2016, 37, 1753-1762.	1.8	9
99	Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1. Acta Biochimica Et Biophysica Sinica, 2021, 53, 547-557.	2.0	9
100	Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2015, 33, 740-740.	1.6	9
101	Analysis of plasma protein biomarkers from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2016, 34, 672-672.	1.6	9
102	Safety, tolerability, and preliminary pharmacokinetic/pharmacodynamic profile of JMT103 in patients with bone metastases from solid tumors: A multicenter, open-label, dose-escalation, phase I clinical study Journal of Clinical Oncology, 2020, 38, 3638-3638.	1.6	9
103	A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma. Oncologist, 2022, 27, e453-e462.	3.7	9
104	Genetic polymorphism of the phospholipase C epsilon 1 gene and risk of gastric cancer. Chinese Medical Journal, 2014, 127, 2511-7.	2.3	9
105	STK15 F31I polymorphism is associated with breast cancer risk: a meta-analysis involving 25,014 subjects. Breast Cancer Research and Treatment, 2009, 118, 599-603.	2.5	8
106	Analysis of expression of transcription factors in early human retina. International Journal of Developmental Neuroscience, 2017, 60, 94-102.	1.6	8
107	A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer. BMC Cancer, 2017, 17, 188.	2.6	8
108	Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 <scp>CONCUR</scp> trial. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1307-1316.	2.8	8

#	Article	IF	CITATIONS
109	Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the PhaseÂ3 FRESCO Trial. Advances in Therapy, 2020, 37, 4585-4598.	2.9	8
110	A randomized, double-blind, parallel-group, placebo-controlled, multicenter, phase II clinical study of famitinib in the treatment of advanced metastatic colorectal cancer Journal of Clinical Oncology, 2015, 33, 513-513.	1.6	8
111	Associations of genotypes and haplotypes of <i>IL-17</i> with risk of gastric cancer in an eastern Chinese population. Oncotarget, 2016, 7, 82384-82395.	1.8	8
112	Genomic Profiling of Chinese Cervical Cancer Patients Reveals Prevalence of DNA Damage Repair Gene Alterations and Related Hypoxia Feature. Frontiers in Oncology, 2021, 11, 792003.	2.8	8
113	A new method of surgical margin assuring for abdominal radical trachelectomy in frozen section. European Journal of Cancer, 2015, 51, 734-741.	2.8	7
114	An integrated analysis of cancer genes in clear cell renal cell carcinoma. Future Oncology, 2017, 13, 715-725.	2.4	7
115	Phase <scp>II</scp> study of Sâ€1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off. Cancer Science, 2017, 108, 2045-2051.	3.9	7
116	DNA-nanorobot-guided thrombin-inducing tumor infarction: raising new potential clinical concerns. Drug Discovery Today, 2020, 25, 951-955.	6.4	7
117	A Phase I/II trial of fruquintinib in combination with paclitaxel for second-line treatment in patients with advanced gastric cancer Journal of Clinical Oncology, 2017, 35, 128-128.	1.6	7
118	Abdominal scar characteristics as a predictor of cervical stenosis after abdominal radical trachelectomy. Oncotarget, 2016, 7, 37755-37761.	1.8	7
119	Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 423-425.	2.2	7
120	Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2016, 34, 507-507.	1.6	7
121	Genetic variant rs4072037 of MUC1 and gastric cancer risk in an Eastern Chinese population. Oncotarget, 2016, 7, 15930-15936.	1.8	6
122	Anticancer drug R&D landscape in China. Journal of Hematology and Oncology, 2020, 13, 51.	17.0	6
123	Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients. BMC Cancer, 2014, 14, 986.	2.6	5
124	A multicenter clinical study: personalized medication for advanced gastrointestinal carcinomas with the guidance of patient-derived tumor xenograft (PDTX). Journal of Cancer Research and Clinical Oncology, 2022, 148, 673-684.	2.5	5
125	Subgroup analysis by prior anti-VEGFor anti-EGFR target therapy in FRESCO,a randomized, double-blind, Phase IIIAtrial. Future Oncology, 2021, 17, 1339-1350.	2.4	5
126	Efficacy and tolerability of bevacizumab (BEV) plus capecitabine and cisplatin (XP) in Chinese patients (pts) with locally advanced or metastatic gastric/gastroesophageal junction cancer (AGC): Results from the AVATAR study Journal of Clinical Oncology, 2012, 30, 73-73.	1.6	5

#	Article	IF	CITATIONS
127	S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil. International Journal of Clinical and Experimental Pathology, 2014, 7, 4274-9.	0.5	5
128	Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China. Chinese Clinical Oncology, 2020, 9, 68-68.	1.2	4
129	UHRF1 regulates alternative splicing by interacting with splicing factors and U snRNAs in a H3R2me involved manner. Human Molecular Genetics, 2021, 30, 2110-2122.	2.9	4
130	A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer Journal of Clinical Oncology, 2014, 32, 3548-3548.	1.6	4
131	A randomized, double-blind, placebo-controlled, multi-centered phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO) Journal of Clinical Oncology, 2017, 35, 3508-3508.	1.6	4
132	Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT Journal of Clinical Oncology, 2016, 34, 519-519.	1.6	4
133	Progressive resistance exercise training to prevent lower-limb lymphedema after cervical cancer surgery: A feasibility study. Asia-Pacific Journal of Oncology Nursing, 2022, 9, 32-38.	1.6	4
134	mPEG-PDLLA Micelles Potentiate Docetaxel for Intraperitoneal Chemotherapy in Ovarian Cancer Peritoneal Metastasis. Frontiers in Pharmacology, 2022, 13, 861938.	3.5	4
135	Effects of variant rs346473 in ARHGAP24 gene on disease progression of HBV infection in han Chinese population. Journal of Huazhong University of Science and Technology [Medical Sciences], 2011, 31, 482-487.	1.0	3
136	Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors. Oncologist, 2017, 22, 638-e56.	3.7	3
137	Improving pregnancy outcomes in fertility preserved cervical cancer patients: big challenge after radical trachelectomy. Journal of Gynecologic Oncology, 2019, 30, e73.	2.2	3
138	A post-hoc health-related quality of life (HRQoL) analysis of patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial Journal of Clinical Oncology, 2015, 33, 667-667.	1.6	3
139	Impact of primary tumor location (TL) on outcomes of first-line (1L) FOLFOX-4 (F) ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial Journal of Clinical Oncology, 2017, 35, 683-683.	1.6	3
140	Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial Journal of Clinical Oncology, 2018, 36, 3521-3521.	1.6	3
141	Initial dose of apatinib in Chinese patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting: 500 mg or 850 mg?. Journal of Clinical Oncology, 2018, 36, 35-35.	1.6	3
142	Treatment patterns and outcomes in Chinese gastric cancer by HER2 status: A non-interventional registry study (EVIDENCE) Journal of Clinical Oncology, 2019, 37, 4025-4025.	1.6	3
143	Effects of regorafenib (REG) therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial Journal of Clinical Oncology, 2015, 33, 3560-3560.	1.6	3
144	Time to raise the bar: Transition rate of phase 1 programs on anticancer drugs. Cancer Cell, 2022, 40, 233-235.	16.8	3

#	Article	IF	CITATIONS
145	Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer. Anti-Cancer Drugs, 2008, 19, 745-748.	1.4	2
146	Reply to C. Kersten et al and D.A. Parikh et al. Journal of Clinical Oncology, 2019, 37, 1592-1593.	1.6	2
147	A phase I study of a TGF- β receptor I kinase inhibitor YL-13027 in patients with advanced solid tumors Journal of Clinical Oncology, 2021, 39, 3098-3098.	1.6	2
148	Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in theÂFRESCO trial. Future Oncology, 2021, 17, 1923-1931.	2.4	2
149	Comparison of efficacy and safety of second-line palliative chemotherapy with paclitaxel plus raltitrexed and paclitaxel alone in patients with metastatic gastric adenocarcinoma: A randomized phase II trial Journal of Clinical Oncology, 2019, 37, 4054-4054.	1.6	2
150	Association between hand-foot skin reaction (HFSR) and survival benefit of fruquintinib in FRESCO trial Journal of Clinical Oncology, 2019, 37, e15012-e15012.	1.6	2
151	LRP5 polymorphism-A potential predictor of the clinical outcome in advanced gastric cancer patients treated with EOF regimen. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 478-85.	2.2	2
152	Phase II study of mitomycin C and cisplatin in heavily pretreated advanced breast cancer. Chinese-German Journal of Clinical Oncology, 2006, 5, 442-445.	0.1	1
153	Immunohistochemical study of nuclear factor-κB activity in colorectal cancer. Chinese-German Journal of Clinical Oncology, 2011, 10, 406-409.	0.1	1
154	Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 70, 57-63.	2.3	1
155	Influence of hypoxia‑related genetic polymorphisms on the prognosis of patients with metastatic gastric cancer treated with EOF. Oncology Letters, 2017, 15, 1334-1342.	1.8	1
156	Reply to P. Di Nardo et al and R. Sun et al. Journal of Clinical Oncology, 2018, 36, 1380-1381.	1.6	1
157	CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) Journal of Clinical Oncology, 2021, 39, TPS255-TPS255.	1.6	1
158	Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer. OncoTargets and Therapy, 2021, Volume 14, 4439-4450.	2.0	1
159	Effects of regorafenib therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial Journal of Clinical Oncology, 2015, 33, 697-697.	1.6	1
160	Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2018, 36, 3537-3537.	1.6	1
161	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESCO trial Journal of Clinical Oncology, 2018, 36, 3544-3544.	1.6	1
162	Development of non-hematological adverse events in apatinib-treated gastric cancer and their association with clinical outcome: Results from a phase IV study Journal of Clinical Oncology, 2018, 36, 4039-4039.	1.6	1

#	Article	IF	CITATIONS
163	Safety of apatinib as third-line or beyond treatment in advanced or metastatic gastric cancer: Results from a multicenter phase IV study (Ahead-G201) Journal of Clinical Oncology, 2018, 36, e16019-e16019.	1.6	1
164	A phase Ia/Ib trial of the anti-PD-L1 human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas Journal of Clinical Oncology, 2019, 37, 2526-2526.	1.6	1
165	Early carcinoembryonic antigen (CEA) dynamics to predict fruquintinib efficacy in FRESCO, a 3+ line metastatic colorectal carcinoma (mCRC) phase III trial Journal of Clinical Oncology, 2020, 38, e16001-e16001.	1.6	1
166	First-in-human (FIH) phase I study of GST-HG161, a potent and highly selective c-met inhibitor, in patients with advanced solid tumor Journal of Clinical Oncology, 2020, 38, e16126-e16126.	1.6	1
167	S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil. International Journal of Clinical and Experimental Pathology, 2014, 7, 3293-8.	0.5	1
168	Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC) Journal of Clinical Oncology, 2022, 40, 281-281.	1.6	1
169	Reply to S. Zhang, L. Fornaro et al, and H.J. Lee et al. Journal of Clinical Oncology, 2016, 34, 3823-3824.	1.6	Ο
170	Clinical effectiveness of apatinib at different doses in patients with advanced gastric cancer as the third-line or further treatment: Results from a post-marketing phase IV study Journal of Clinical Oncology, 2021, 39, e16037-e16037.	1.6	0
171	A phase Ib study of the PI3K δ inhibitor linperlisib in patients with advanced solid tumors. . Journal of Clinical Oncology, 2021, 39, 3099-3099.	1.6	0
172	Safety and efficacy of apatinib as third or later line treatment for advanced gastric cancer or gastroesophageal junction adenocarcinoma: A post-marketing phase IV study Journal of Clinical Oncology, 2021, 39, e16034-e16034.	1.6	0
173	WX390, a high-potent PI3K-mTOR dual inhibitor, first-in-human (FIH) phase I study in advanced relapsed or refractory solid tumor, and lymphoma Journal of Clinical Oncology, 2021, 39, 3106-3106.	1.6	0
174	Ultrasoundâ \in guided percutaneous transluminal angioplasty for the treatment of cephalic arch stenosis in hemodialysis arteriovenous fistulas. Seminars in Dialysis, 2021, , .	1.3	0
175	Effects of IGF2BP2, KCNQ1, and GCKR polymorphisms on clinical outcome in metastatic gastric cancer treated with EOF regimen Journal of Clinical Oncology, 2015, 33, 64-64.	1.6	0
176	Post-hoc analyses of overall survival (OS) and progression-free survival (PFS) in the TRIO-013/LOGiC trial of lapatinib (L) in combination with capecitabine plus oxaliplatin (CapeOx) Journal of Clinical Oncology, 2015, 33, 133-133.	1.6	0
177	Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT Journal of Clinical Oncology, 2015, 33, 705-705.	1.6	0
178	Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT Journal of Clinical Oncology, 2016, 34, 3538-3538.	1.6	0
179	Outcomes by hypomagnesemia in the randomized phase III ASPECCT trial in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2016, 34, e15050-e15050.	1.6	0
180	A phase III trial (ZJBIO009): CMAB009 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer patients Journal of Clinical Oncology, 2017, 35, 3513-3513.	1.6	0

#	Article	IF	CITATIONS
181	Comparison of efficacy and safety of first-line palliative chemotherapy with TX and XELOX regimens in patients with metastatic gastric adenocarcinoma: A randomized phase II trial Journal of Clinical Oncology, 2017, 35, 4070-4070.	1.6	0
182	Early presence of antiangiogenesis-related adverse events as a potential biomarker of antitumor efficacy in patients with metastatic gastric cancer treated with apatinib Journal of Clinical Oncology, 2017, 35, 4052-4052.	1.6	0
183	Effect of region and hospital attribute on outcome of gastric patients treated with apatinib: Data from post-marketing phase IV study Journal of Clinical Oncology, 2018, 36, 40-40.	1.6	0
184	Apatinib as third-line or beyond therapy in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction: An open-label, multicenter, post-marketing phase IV study (Ahead-G201) Journal of Clinical Oncology, 2018, 36, 103-103.	1.6	0
185	Association of proteinuria, hypertension, and hand-foot-skin reaction with efficacy of apatinib in gastric cancer: Results from the post-marketing study (Ahead-G201) Journal of Clinical Oncology, 2018, 36, 73-73.	1.6	0
186	Safety and efficacy of apatinib in elderly patients with advanced or metastatic gastric cancer in the post-marketing phase IV study: Subgroup analysis by age (Ahead-G201) Journal of Clinical Oncology, 2018, 36, 126-126.	1.6	0
187	Prognostic factors for survival in apatinib-treated gastric cancer: Results from a post-marketing phase IV study (Ahead-G201) Journal of Clinical Oncology, 2018, 36, 19-19.	1.6	0
188	Comparisons between intestinal and diffuse gastric cancer in response to apatinib: Data from post-marketing phase IV study Journal of Clinical Oncology, 2018, 36, 36-36.	1.6	0
189	Effects of apatinib dose interruptions on safety and efficacy in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting Journal of Clinical Oncology, 2018, 36, 142-142.	1.6	0
190	Does hypertension history in patients with advanced gastric cancer has an impact on clinical outcomes following apatinib treatment? A subgroup analysis based on data from Ahead-G201 study Journal of Clinical Oncology, 2018, 36, e16022-e16022.	1.6	0
191	BMI differences for clinical outcome in patients with advanced or metastatic gastric cancer treated with apatinib: Data from a post-marketing phase IV study (Ahead-G201) Journal of Clinical Oncology, 2018, 36, e16027-e16027.	1.6	0
192	Impact of time to progression on first-line therapy on clinical outcomes in advanced gastric cancer treated with apatinib: data from a phase IV study (Ahead-G201) Journal of Clinical Oncology, 2018, 36, e16021-e16021.	1.6	0
193	Clinical benefit of continuing apatinib beyond progression in advanced or metastatic gastric cancer Journal of Clinical Oncology, 2018, 36, e16020-e16020.	1.6	0
194	Effect of ECOG PS on outcome of advanced or metastatic gastric patients treated with apatinib: Analysis from a post-marketing phase IV study Journal of Clinical Oncology, 2018, 36, e16026-e16026.	1.6	0
195	Response to apatinib by the number of metastatic organs in patients with advanced or metastatic gastric cancer: Subgroup analysis from a phase IV study (Ahead-G201) Journal of Clinical Oncology, 2018, 36, e16028-e16028.	1.6	0
196	Sequencing of different targeted therapies in management of KRAS wild-type metastatic colorectal cancer: A meta-analysis Journal of Clinical Oncology, 2019, 37, 679-679.	1.6	0
197	Camrelizumab plus famitinib in patients with metastatic colorectal cancer: Results from an open-label, multicenter phase II basket study Journal of Clinical Oncology, 2022, 40, 3577-3577.	1.6	0
198	Preliminary results of raltitrexed in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, real-world study Journal of Clinical Oncology, 2022, 40, 3591-3591.	1.6	0

		Jin Li	
#	Article	IF	CITATIONS
199	Updated efficacy and safety results from the phase 2 study of serplulimab, a novel anti-PD-1 antibo in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors Journal of Clinical Oncology, 2022, 40, 2592-2592.	dy, 1.6	5 0